Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1106Carcinoma, Renal Cell 412Urinary Bladder Neoplasms 280Kidney Neoplasms 177Neoplasm Metastasis 134Neoplasms 132Carcinoma, Non-Small-Cell Lung 109Carcinoma, Transitional Cell 108Breast Neoplasms 94Melanoma 90Ovarian Neoplasms 70Lung Neoplasms 67Colorectal Neoplasms 58Pancreatic Neoplasms 49Sarcoma 48Wilms Tumor 41Uterine Cervical Neoplasms 37Head and Neck Neoplasms 37Stomach Neoplasms 36Testicular Neoplasms 33Non-Muscle Invasive Bladder Neoplasms 33Esophageal Neoplasms 33Squamous Cell Carcinoma of Head and Neck 31Neuroblastoma 30Lymphoma, Non-Hodgkin 29Colonic Neoplasms 28Small Cell Lung Carcinoma 27Carcinoma, Hepatocellular 27Urethral Neoplasms 25Triple Negative Breast Neoplasms 23

Interventions

berzosertib 1Platinum 1Gemcitabine 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Metastatic Bladder Urothelial Carcinoma × Genitourinary × Clear all
NCT02567409 2025-03-03

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
87 enrolled 13 charts
Genitourinary

Metastatic Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡